National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

Found 479 cases where Vaccine targets Measles (MEA or MER or MM or MMR or MMRV) and Patient Died and Vaccination Date on/before '2018-11-30'

Case Details

This is page 28 out of 48

Result pages: prev   19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37   next


VAERS ID: 801759 (history)  
Form: Version 2.0  
Age: 1.0  
Sex: Unknown  
Location: Unknown  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 0000-00-00
Entered: 2019-02-15
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Unknown       Purchased by: ?
Symptoms: B-lymphocyte count, Biopsy skin abnormal, Bone marrow disorder, CD4 lymphocytes decreased, Death, Dermatitis, Dermatitis psoriasiform, Hepatitis, Immunodeficiency, Immunoglobulin therapy, Immunology test, Immunology test abnormal, Inflammation, Laryngeal inflammation, Natural killer cell count, Nephritis, Polymerase chain reaction positive, Progressive multifocal leukoencephalopathy, Pyoderma gangrenosum, Rubella, Rubivirus test positive, Skin lesion, Stomatitis, T-lymphocyte count decreased, Vaccination complication
SMQs:, Acute renal failure (broad), Hepatitis, non-infectious (narrow), Severe cutaneous adverse reactions (broad), Haematopoietic cytopenias affecting more than one type of blood cell (broad), Haematopoietic leukopenia (narrow), Systemic lupus erythematosus (broad), Malignancy related conditions (narrow), Malignancy related therapeutic and diagnostic procedures (narrow), Oropharyngeal conditions (excl neoplasms, infections and allergies) (narrow), Demyelination (narrow), Skin tumours of unspecified malignancy (broad), Hypersensitivity (narrow), Myelodysplastic syndrome (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Opportunistic infections (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Cartilage-hair hypoplasia; Granuloma skin
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: US0095075131902USA004788

Write-up: This literature marketed report has been received from the authors of a published literature article, and refers to a 15-year-old patient of unknown gender. The patient''s concurrent condition included cartilage hair hypoplasia, reported as inherited immunodeficiency and cutaneous granuloma. The patient''s medical history and concomitant were not reported. On an unknown date at the age of 1 year, the patient was vaccinated with M-M-R II (dose, route of administration, lot # and expiration date were not reported) for prophylaxis. On an unknown date, the patient developed immunodeficiency-related vaccine-derived rubella virus (iVDRV). The patient had skin involvement that was described as initially psoriasiform or resembling pyoderma gangrenosum. The patient had chronic inflammation in skin, liver, kidney, larynx, palate and bone marrow but rubella was detected by immunofluorescence or polymerase chain reaction (PCR) in skin, liver and kidney. The Rubella capsid protein was detected and the iVDRV strain with multiple non-overlapping mutations was identified in the skin biopsy by sequencing viral genomes. The patient''s CD3 count was 550 cells/uL, CD4 count was 450 cells/uL, CD19 count was 120 cells/uL and natural killer (NK) cell count was 120 cells/uL. The authors assessed CD3 and CD4 count as low, and NK count as normal. The patient was treated with azathioprine, azithromycin, mycophenolic acid and intravenous immunoglobulin (IVIG) with no improvement. The patient received also cyclosporine and steroids with partial response. Nitazoxanide was used largely as salvage therapy in this extremely ill patient but it had no obvious benefit. After 2 months of treatment with nitazoxanide, lesions in the skin, liver and kidney improved and improvement was sustained until the patient''s death. The patient died from progressive multifocal leukoencephalopathy (PML). The authors considered the iVDRV to be related to M-M-R II. Upon internal review, the iVDRV was determined to be medically significant as the patient was treated with immunoglobulin therapy. This is one of seven reports derived from the same literature article (linked # 1902USA004783, 1902USA004784, 1902USA004785, 1902USA004786, 1902USA004787, 1902USA003143). Sender''s Comments: US-009507513-1902USA003143.


VAERS ID: 804320 (history)  
Form: Version 2.0  
Age: 2.0  
Sex: Male  
Location: Unknown  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 0000-00-00
Entered: 2019-03-05
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
FLUX: INFLUENZA (SEASONAL) (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK UN / UN
MMRV: MEASLES + MUMPS + RUBELLA + VARICELLA (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK UN / UN

Administered by: Unknown       Purchased by: ?
Symptoms: Anaphylactic reaction, Autopsy, Cardio-respiratory arrest, Death, Tryptase increased
SMQs:, Torsade de pointes/QT prolongation (broad), Anaphylactic reaction (narrow), Arrhythmia related investigations, signs and symptoms (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (narrow), Anaphylactic/anaphylactoid shock conditions (narrow), Acute central respiratory depression (broad), Hypersensitivity (narrow), Respiratory failure (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Cyanosis (The patient had periodic cyanosis.)
Preexisting Conditions: Medical History/Concurrent Conditions: Cavopulmonary anastomosis (The patient had hypoplastic left heart syndrome with subsequent cavopulmonary shunt procedure.); Hypoplastic left heart syndrome (The patient had hypoplastic left heart syndrome with subsequent cavopulmonary shunt procedure.); Premature birth (The patient was born premature at 33 weeks gestation.)
Allergies:
Diagnostic Lab Data: Test Name: Serum tryptase level; Result Unstructured Data: Increased.
CDC Split Type: USSEQIRUS201902085

Write-up: This is a literature case, initially received on 19-Feb-2019, concerning a 2-year-old, male child. The study describes the reports of anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS) during 1990-2016. A descriptive analysis, including history of hypersensitivity (anaphylaxis, respiratory allergies, and drug allergies) and vaccines given were performed. The patient''s medical history included premature birth at 33 weeks of gestation, hypoplastic left heart syndrome with subsequent cavopulmonary shunt procedure. The current conditions of the patient included periodic cyanosis. On an unspecified date, the patient was administered INN Flu Vaccine Seasonal (anatomical location, dose, route of administration, batch number, manufacturer, trade name and expiry date: not reported) for an unknown indication. On the same day, the patient was also administered a combined non-company suspect vaccine, Measles vaccine;Mumps vaccine;Rubella vaccine;Varicella zoster vaccine (anatomical location, dose, route of administration, batch number, manufacturer, trade name and expiry date: not reported) for an unknown indication. On the same day, 20 minutes after the vaccination, the patient experienced a cardiopulmonary arrest and the patient died. Autopsy was performed, and the cause of death was reported as anaphylactic reaction (related). On post-mortem laboratory tests revealed an increased serum tryptase level. The outcome of the event cardiopulmonary arrest was not reported. The reporter assessed this case as serious (death).; Reporter''s Comments: A 2-year-old, male patient with medical history/concurrent condition (premature birth at 33 weeks of gestation, hypoplastic left heart syndrome with subsequent cavopulmonary shunt procedure and periodic cyanosis) experienced fatal cardiopulmonary arrest, 20 minutes after administration of INN Flu Vaccine. The autopsy reported the cause of death as anaphylactic reaction. The case meets level 2 of Brighton Collaboration criteria of diagnostic certainty for anaphylactic reaction. Considering the plausible temporal relationship between vaccination and reported fatal events (anaphylactic reaction and cardiopulmonary arrest) and lack of alternative more plausible causes, the company conservatively assessed the events as possibly related to suspect vaccine. However, co-administered combined measles, mumps, rubella and varicella vaccine was considered as non company suspect in this case. The company assessed the event ''anaphylactic reaction'' as serious (medically significant).; Reported Cause(s) of Death: Anaphylactic reaction.


VAERS ID: 809662 (history)  
Form: Version 2.0  
Age: 1.0  
Sex: Male  
Location: Nebraska  
Vaccinated:2016-04-11
Onset:2016-04-21
   Days after vaccination:10
Submitted: 0000-00-00
Entered: 2019-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HEPA: HEP A (NO BRAND NAME) / UNKNOWN MANUFACTURER - / 1 UN / UN
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. - / 1 LG / SYR
VARCEL: VARICELLA (NO BRAND NAME) / UNKNOWN MANUFACTURER - / 1 UN / UN

Administered by: Private       Purchased by: ?
Symptoms: Brain death, Brain injury, Brain scan abnormal, Crying, Dark circles under eyes, Death, Diarrhoea, Hypophagia, Hypotonia, Pyrexia, Sepsis, Vomiting
SMQs:, Acute pancreatitis (broad), Peripheral neuropathy (broad), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Pseudomembranous colitis (broad), Malignancy related therapeutic and diagnostic procedures (narrow), Guillain-Barre syndrome (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Conditions associated with central nervous system haemorrhages and cerebrovascular accidents (broad), Depression (excl suicide and self injury) (broad), Hypotonic-hyporesponsive episode (broad), Generalised convulsive seizures following immunisation (broad), Noninfectious diarrhoea (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Sepsis (narrow), Opportunistic infections (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2016-04-24
   Days after onset: 3
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? No
Previous Vaccinations:
Other Medications: None
Current Illness: None
Preexisting Conditions: None
Allergies: None
Diagnostic Lab Data: I don''t have access to his exact record anymore. I know they did a scan of his brain which showed he was brain dead. He was declared deceased on 4/24/16
CDC Split Type:

Write-up: Woke up with a fever of 101, crying, diarrhea. Gave him a cool bath after changing him to get him clean/cool him down. He could not grab the water from the faucet, he missed it as if his hand wasn''t going where his brain told to. Tried to give him water, he wouldn''t drink any. He snuggled back to sleep, we transferred him to his crib. At 9am, he threw up in his sleep without even stirring, eyes had deep dark circles. We picked him up and he was limp. We took him to the ER where they said had severe brain damage. They treated him for sepsis.


VAERS ID: 813610 (history)  
Form: Version 2.0  
Age: 50.0  
Sex: Female  
Location: Pennsylvania  
Vaccinated:2018-10-19
Onset:2018-10-20
   Days after vaccination:1
Submitted: 0000-00-00
Entered: 2019-05-11
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
DTAP: DTAP (DAPTACEL) / SANOFI PASTEUR - / UNK UN / UN
FLU4: INFLUENZA (SEASONAL) (AFLURIA QUADRIVALENT) / SEQIRUS, INC. - / UNK UN / UN
HEP: HEP B (ENGERIX-B) / GLAXOSMITHKLINE BIOLOGICALS - / UNK UN / UN
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Private       Purchased by: ?
Symptoms: Autopsy, Death, Myocardial infarction, Myocarditis, Nausea
SMQs:, Acute pancreatitis (broad), Myocardial infarction (narrow), Embolic and thrombotic events, arterial (narrow), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Cardiomyopathy (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2018-10-21
   Days after onset: 1
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: aspirin; lisinopril; LOPRESSOR; NORCO; MIRALAX; XANAX
Current Illness: CHF and Cardiomyopathy
Preexisting Conditions: None known
Allergies: COREG; ketorolac; ROBAXIN; SKELAXIN; tramadol
Diagnostic Lab Data: Autopsy done 10/22/2018. Marked changes to the heart muscle suggests of remote myocarditis
CDC Split Type:

Write-up: Became nauseous all day Saturday and Sunday morning, had heart attack Sunday in morning


VAERS ID: 834405 (history)  
Form: Version 2.0  
Age: 1.0  
Sex: Male  
Location: Arkansas  
Vaccinated:2018-09-19
Onset:2018-09-19
   Days after vaccination:0
Submitted: 0000-00-00
Entered: 2019-09-18
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HEPA: HEP A (HAVRIX) / GLAXOSMITHKLINE BIOLOGICALS - / 1 LG / IM
HIBV: HIB (PEDVAXHIB) / MERCK & CO. INC. - / 4 LG / IM
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. - / 1 LG / IM
PNC13: PNEUMO (PREVNAR13) / PFIZER/WYETH - / 4 LG / IM
VARCEL: VARICELLA (VARIVAX) / MERCK & CO. INC. - / 1 LG / IM

Administered by: Private       Purchased by: ?
Symptoms: Decreased appetite, Pyrexia
SMQs:, Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2018-09-22
   Days after onset: 3
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: None.
Current Illness: None.
Preexisting Conditions: None.
Allergies: None.
Diagnostic Lab Data:
CDC Split Type:

Write-up: Running a fever, loss of appetite.


VAERS ID: 858617 (history)  
Form: Version 2.0  
Age:   
Sex: Female  
Location: Unknown  
Vaccinated:2009-08-12
Onset:2009-08-19
   Days after vaccination:7
Submitted: 0000-00-00
Entered: 2020-01-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HIBV: HIB (PEDVAXHIB) / MERCK & CO. INC. - / UNK - / -
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. - / UNK - / -
PPV: PNEUMO (PNEUMOVAX) / MERCK & CO. INC. - / UNK - / -
VARCEL: VARICELLA (VARIVAX) / MERCK & CO. INC. - / 1 - / -

Administered by: Unknown       Purchased by: ?
Symptoms: Acute respiratory distress syndrome, Acute respiratory failure, Blood albumin decreased, Blood culture positive, Bronchoalveolar lavage abnormal, Bronchospasm, CD4 lymphocytes normal, CD8 lymphocytes decreased, Candida infection, Chest X-ray abnormal, Complement factor normal, Culture urine positive, Death, Dysphagia, Dyspnoea, Endotracheal intubation, Grunting, Hypotonia, Irritability, Lung infiltration, Lung opacity, Mechanical ventilation, Multiple organ dysfunction syndrome, Muscular weakness, Neutrophil count increased, Pneumonia viral, Pneumothorax, Polymerase chain reaction positive, Pseudomonas infection, Pseudomonas test positive, Pulmonary oedema, Pyrexia, Rash maculo-papular, Rash vesicular, Respiratory disorder, Respiratory distress, Scab, Sepsis, Skin lesion, Stridor, T-lymphocyte count decreased, Tachypnoea, Upper respiratory tract infection, Use of accessory respiratory muscles, Varicella virus test positive, Varicella zoster virus infection, White blood cell count normal
SMQs:, Torsade de pointes/QT prolongation (broad), Rhabdomyolysis/myopathy (broad), Cardiac failure (narrow), Anaphylactic reaction (broad), Angioedema (broad), Asthma/bronchospasm (narrow), Haematopoietic leukopenia (narrow), Peripheral neuropathy (broad), Interstitial lung disease (narrow), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (broad), Torsade de pointes, shock-associated conditions (broad), Hypovolaemic shock conditions (broad), Toxic-septic shock conditions (broad), Anaphylactic/anaphylactoid shock conditions (broad), Hypoglycaemic and neurogenic shock conditions (broad), Acute central respiratory depression (narrow), Pulmonary hypertension (broad), Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (broad), Hostility/aggression (broad), Haemodynamic oedema, effusions and fluid overload (narrow), Cardiomyopathy (broad), Eosinophilic pneumonia (broad), Hypotonic-hyporesponsive episode (broad), Generalised convulsive seizures following immunisation (broad), Hypersensitivity (narrow), Respiratory failure (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (narrow), Hypoglycaemia (broad), Infective pneumonia (narrow), Sepsis (narrow), Opportunistic infections (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2009-11-02
   Days after onset: 75
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? Yes
Previous Vaccinations:
Other Medications: FERRIN; POLY-VI-SOL; nystatin; BACTROBAN; lansoprazole
Current Illness: Anaemia; Bronchiolitis; Chromosome abnormality; Developmental delay; Failure to thrive; Feeding disorder; Gastrooesophageal reflux disease; Hypotonia; Muscular dystrophy; Pneumonia aspiration; Prophylaxis; Protein allergy; Respiratory syncytial virus infection
Preexisting Conditions: Medical History/Concurrent Conditions: Gastrostomy tube insertion; Hospitalisation; Mechanical ventilation; Otitis media; Varicella
Allergies:
Diagnostic Lab Data: Test Date: 20090924; Test Name: bronchial lavage specimen collected; Test Result: Positive ; Test Date: 20091009; Test Name: bronchial lavage specimen collected; Test Result: Positive
CDC Split Type: US0095075131210USA006581

Write-up: Another episode of respiratory distress/ Severe respiratory complications that worsened with each new crop of varicella lesions; severe respiratory complication/distress; the patient may have underlying immunosuppression for which varicella vaccination contraindicated; episode of acute respiratory failure/multi-organ failure; episode of acute respiratory failure/multi-organ failure; Rash on hands disseminated into a generalized maculopapular vesicular rash/recurrent crops of maculopapular vesicular skin lesions/ Varicella-like rash/Severe respiratory complications that worsened with each new crop of varicella lesions; bilateral pneumothoraces; sepsis; bilateral interstitial infiltrates consistent with viral pnenmonia, with worsening interstitial edema and opacification; This spontaneous report as received from an other health professional describing in a draft of the manuscript referring a case of fatal varicella due to vaccine-strain VZV following vaccination with varicella virus vaccine live (Oka/Merck) (VARIVAX). A 15-month old child who developed a varicella-like rash 20 days after varicella virus vaccine live (Oka/Merck) (VARIVAX) that lasted for 2 months despite continued acyclovir treatment. The rash was confirmed to be due to varicella virus vaccine live (Oka/Merck) (VARIVAX). The patient developed severe respiratory complications that worsened with each new crop of varicella lesions; vaccine-strain VZV was detected in the bronchial lavage specimen. Sepsis and multi-organ failure led to death. The patient did not have any diagnosed immuno-compromising conditions for which varicella vaccination would have been contraindicated, but did have a number of underlying conditions that were severe enough to have required several hospitalizations in the past and might have been indicative of underlying immuno-compromising. The possibility of acyclovir resistance and a change in antiviral therapy to foscarnet should be considered if lesions do not improve after 10 days of treatment. Varicella virus vaccine live (Oka/Merck) (VARIVAX) was introduced in 1995. It contains live attenuated varicella-zoster virus (VZV). The routine childhood varicella vaccination program in the country has led to substantial declines in varicella related morbidity and mortality. Serious adverse events reported to the Vaccine Adverse Event Reporting System were rare; those confirmed to be due to the vaccine-strain VZV include pneumonia, hepatitis, herpes zoster with meningitis, and severe rash. The patient received her first dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) on 12-AUG-2009, along with vaccinations against measles, mumps, rubella, haemophilus influenza b, and pneumococcal disease at age 1-year. She was born healthy, weighing 6.9 pounds; mother had no pregnancy complications. She did not have any recognized immuno-compromising conditions. Her newborn blood spot was negative for severe combined immunodeficiency. The patient had a milk protein allergy, anemia and chromosomal abnormality. She had a history of global developmental delay, failure to thrive (weight 14 pounds at age 15 months), type 2 muscular dystrophy, profound hypotonia, gastroesophageal reflux disease, otitis media and varicella. She had a gastrostomy tube placed at age 9-months due to poor feeding. She had episodes of bronchiolitis, pneumonia due to respiratory syncytial virus infection (RSV), and aspiration pneumonia (recurrent) that resulted in 5 hospitalizations before her first birthday, two of which required mechanical ventilation. Her only routine medication at the time of vaccination was lansoprazole. Quantitative serum immuno-globulin levels measured at 10 months were normal, except for elevated IgE levels at 424 (normal range: 0.8-7.3 IV/ml^17). On week after vaccination (19-AUG-2009), the patient was hospitalized for severe respiratory distress and was treated with albuterol, budesonide, and amoxicillin clavulanate. On the hospital day 10 (16 days post-vaccination) (29-AUG-2009), she was started on methylprednisolone iv, 3.5 mg q 12 for 3 days (equivalent to 8.8 mg/day of prednisone) followed by prednisolone via g-tube 3.5 mg ql2 for 2 days (equivalent to 7.0 mg/day of prednisone). Her respiratory distress resolved and she was discharged on hospital day 14 (01-SEP-2009). On the day of hospital discharge (01-SEP-2009), her mother noticed a rash on one of her hands that disseminated into a generalized maculopapular vesicular rash by the next day (02-SEP-2009), at which point, she was seen by her primary care physician and started on oral acyclovir. A skin lesion specimen collected on the next day (20 days post-vaccination) (02-SEP-2009) was positive for vaccine-strain VZV by polymerase chain reaction. Four days after rash onset (05-SEP-2009), the patient developed another episode of respiratory distress and was hospitalized. On admission, she had diffuse vesicular and crusted lesions and was febrile to 104 F. Chest x-ray showed increased opacity in the left lung. She was switched to IV acyclovir and was started on broad-spectrum antibiotics. Starting on hospital day 4 (09-SEP-2009), she received IV methylprednisolone (12 mg 1 dose for 1 day then 6 mg qd for 2 days), followed by 2 doses of prednisolone for one day. On hospital day 11 (16-SEP-2009), the patient had an episode of acute respiratory failure and was intubated. She required high-frequency oscillatory ventilation until her death 7 weeks later (02-NOV-2009). IV acyclovir was discontinued on hospital day 12 (17-SEP-2009), restarted on hospital day 21 (26-SEP-2012), and she was remained on it until her death. On hospital day 24 (29-SEP-2009), she was started on low-dose prolonged steroid therapy protocol for acute respiratory distress syndrome (IV methyl prednisolone for 32 days, starting with 13 mg for 1 dose and tapered to 0.4 mg bid). Despite ongoing acyclovir treatment, she continued to develop recurrent crops of maculopapular vesicular skin lesions every 7-8 days throughout her hospitalization. Her respiratory status deteriorated with each new crop of lesions and the chest x-ray showed bilateral interstitial infiltrates consistent with viral pneumonia that became increasingly confluent, with worsening interstitial edema and opacification. The patient subsequently developed bilateral pneumothoraces. On the day of her death, she had 50-100 skin lesions. A bronchial lavage specimen collected on hospital day 19 (24-SEP-2009) was positive for VZV DNA and later confirmed to be vaccine-strain VZV; an additional bronchial lavage specimen collected on hospital day 34 (09-OCT-2009) was also VZV-positive but not genotyped. Blood, respiratory, and tracheal aspirate specimens collected between days 12-19 (17-SEP-2009 to 24-SEP-2009) of hospitalization were positive for Pseudomonas aeruginosa by culture and several urine specimens collected between days 20-44 (25-SEP-2009 to 19-OCT-2009) of hospitalization were positive for Candida albicans by culture. Blood collected on day 11 (16-SEP-2009) of hospitalization showed normal humoral immunity and complement levels. A T-cell deficiency was considered as the patient''s T-cell counts on hospital days 11 (16-SEP-2009) and 17 (25-SEP-2009) were lower than normal: absolute T-cell counts were 223 and 864 respectively (normal range: 1600-6700); CD-8 counts were 46 and 180 (normal range: 400-2100); and CD-4 counts were 169 and 656 (normal range: 1000-4600). It is unknown why the patient described in this report had a prolonged rash that was unresponsive to acyclovir therapy. The patient may have had depressed T-cell function. This case-patient''s symptoms may have been exacerbated by treatment with steroids 2 weeks after vaccination. Although the steroid dosage used to treat this case would not be classified as high-dose, it still may have been immuno-suppressive. The benefits of varicella vaccination outweigh the very low risk of serious adverse events occurring. Providers should carefully monitor for any signs of adverse reactions after vaccination among all persons, especially among persons with medical histories that may be indicative of an immuno-suppressive condition. If these persons develop a rash after vaccination, they should be immediately treated with acyclovir. Death certificate received Date of death 02-NOV-2009, cause of death: multisystem organ failure, acute respiratory distress syndrome, varicella pneumonitis,varicella lesions and sepsis. Discharge summary received for date 27-AUG-2009: DX: respiratory difficulty, bronchospasms, hypotonia. Chief c/o respiratory distress, URI*1day, fever, tachypnea, retractions. Caretaker reports patient having difficulty breathing, fever, irritable. Assessment, (+)fever, grunting, retractions, hypotonia, O2 sat 91% on 3LNC. Speech and swallow eval: oropharyngeal dysphagia. Patient improved over 3 days, stable at discharge. ER/hospital 05-SEP-2009 to 29-OCT-2009. DX: muscular weakness disorder, viral pneumonitis, varicella. Respiratory distress, fever. Parent stated varicella vaccine on 12-AUG-2009. Varicella skin rash formed 31-AUG-2009. EMS presented patient to ER. Assessment: stridor, rash, fever, mild distress. Patient admitted and following day respiratory distress increased, grunting, increas in fever 103F, patient found to be irritable, O2 sats 92% with O2 therapy. TYLENOL was given, within 30 min temperature of 104.5F. One hour later patient heart rate 220-240 bpm. Patient later was stabilized but prognosis was guarded. Follow up information received which stated that the patients lymphoid subsets were all within normal range(CD8 and CD4 T cell percentages were 14% and 51% respectively). Her white blood cell counts were within normal range, neutrophil levels were high at times. her new born blood spot testing performed post mortem was negative for severe combined immunodeficiency/severe T-cell lymphopenia and the result would not exclude severe primary immune deficiencies with detectable T cells but impaired T cell function. In addition, nutritional status can impact T-cell function. One indication of such a problem was low albumin (2.2-2.9 g/dL on multiple samples; normal 3.4-3.S g/dL), with the nadir recorded on hospital day 26. Vaccine-strain VZV in skin and bronchial lavage specimens was identified by real-time PCR targeting 4 vaccine associated single nucleotide polymorphisms at open reading frame (ORF) 3S, ORF 54, and ORF 62. A copy of the published article is attached as further documentation of the patient''s experience. All telephone attempts to obtain follow-up information have been unsuccessful. Follow up information was received on 18-OCT-2013 which reported that, a phone call was received from a physician in regards to Literature Article. The physician was unable to provide any patient or medical information. The physician stated there was no copy of the patients'' Death Certificate and/or a copy of the patient''s Autopsy Results available for her to share, at this time. Additional information has been requested. Follow-up social media report has been received from an unspecified reporter via a journal published. The patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) reconstituted with sterile diluent (lot # and expiration date were unknown). Causality assessment of sterile diluent with all the events was related. It has been determined that case # {US-009507513-2001USA005128} is a duplicate of case # {US-009507513-1210USA006581}. Therefore, case # {US-009507513-2001USA005128} is being deleted from our files and the cases are consolidated into case # {US-009507513-1210USA006581}.; Reported Cause(s) of Death: multisystem organ failure; acute respiratory distress; sepsis; varicella lesions; varicella pneumonitis


VAERS ID: 862933 (history)  
Form: Version 2.0  
Age:   
Sex: Female  
Location: Unknown  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 0000-00-00
Entered: 2020-02-25
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HEPA: HEP A (VAQTA) / MERCK & CO. INC. - / UNK - / -
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. - / UNK - / -

Administered by: Unknown       Purchased by: ?
Symptoms: Death, General physical health deterioration, Organ failure, Renal failure
SMQs:, Rhabdomyolysis/myopathy (broad), Acute renal failure (narrow), Retroperitoneal fibrosis (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (broad), Torsade de pointes, shock-associated conditions (broad), Hypovolaemic shock conditions (broad), Toxic-septic shock conditions (broad), Anaphylactic/anaphylactoid shock conditions (broad), Hypoglycaemic and neurogenic shock conditions (broad), Chronic kidney disease (narrow), Tumour lysis syndrome (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2020-02-10
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Sterile Diluent
Current Illness: Pulmonary hypertension
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: US0095075132002USA009134

Write-up: RENAL FAILURE; ORGAN FAILURE; Deterioated quickly; This spontaneous report was received from a nurse via company representative refers to a 40 year old female patient (nurse''s cousin). The patient''s concurrent condition included pulmonary hypertension. The patient''s medical history, concomitant medication, drug reactions and allergies were not reported. It was reported that the patient was awaiting for a heart and double lung transplant. On an unknown date, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) and hepatitis a vaccine, inactivated (manufacturer unknown) (strength, dose, route of administration, anatomical location, lot# and expiration date was not reported for both the suspect therapies) for prophylaxis. The vaccines were reconstituted with sterile diluent (MERCK STERILE DILUENT) (strength, dose, indication, route of administration, lot# and expiration date was not reported). On an unknown date after receiving the vaccines, the patient experienced quick deterioration and went into organ and renal failure (organ failure, general physical health deterioration and renal failure). On 10-FEB-2020, the patient died. It was unknown if an autopsy was performed. The cause of death was not reported. Causality was not reported. No product quality complaint (PQC) was involved with this report. Upon internal review, the event of renal failure was determined to be medically significant.


VAERS ID: 25010 (history)  
Form: Version 1.0  
Age: 1.7  
Sex: Male  
Location: Foreign  
Vaccinated:1989-10-29
Onset:1989-12-01
   Days after vaccination:33
Submitted: 0000-00-00
Entered: 1990-07-02
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. A2223P / UNK - / -

Administered by: Private       Purchased by: Unknown
Symptoms: Bronchitis
SMQs:

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations: ~ ()~~~In patient
Other Medications: Promethanzine HCL given 21Dec89-21Dec89
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: Dianostic test - Autopsy, Date Dec89 , comment - Streptococcal tracheobronchitis
CDC Split Type: WAES90060362

Write-up: 17 mon. male, received 29Oct89 MMR vaccine 1 dose. 21Dec89 received therapy w/ Promethazine HCL, HS. 22Dec89 infant found dead. Post mortem revealed acute Streptococcal tracheobronchitis.


VAERS ID: 25066 (history)  
Form: Version 1.0  
Age: 1.0  
Sex: Female  
Location: Foreign  
Vaccinated:0000-00-00
Onset:1988-07-13
Submitted: 1988-10-26
   Days after onset:105
Entered: 1990-07-09
   Days after submission:621
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MM: MEASLES + MUMPS (MM-VAX) / MERCK & CO. INC. - / UNK - / -

Administered by: Unknown       Purchased by: Unknown
Symptoms: Apnoea, Bradycardia, Pyrexia, Tachycardia, Vomiting, Weight decreased
SMQs:, Acute pancreatitis (broad), Hyperglycaemia/new onset diabetes mellitus (broad), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Arrhythmia related investigations, signs and symptoms (broad), Acute central respiratory depression (narrow), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Respiratory failure (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Dehydration (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations: ~ ()~~~In patient
Other Medications:
Current Illness:
Preexisting Conditions: no relevant history
Allergies:
Diagnostic Lab Data: CSF 973 mg/dl comment protein
CDC Split Type: ARR47.344

Write-up: Pt vaccinated w/ MMVAX, developed fever, weight loss, vomiting, apena, tachycardia, bradycardia & subsequently died.


VAERS ID: 37898 (history)  
Form: Version 1.0  
Age: 11.0  
Sex: Male  
Location: Foreign  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 0000-00-00
Entered: 1991-12-13
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. - / UNK - / -

Administered by: Unknown       Purchased by: Unknown
Symptoms: Encephalitis, Headache, Meningitis, Stupor, Vomiting
SMQs:, Acute pancreatitis (broad), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Noninfectious encephalitis (narrow), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (narrow), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Hypoglycaemia (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations: ~ ()~~~In patient
Other Medications: UNK
Current Illness:
Preexisting Conditions: No relevant hx
Allergies:
Diagnostic Lab Data: CSF-Microscopy, unremarkable; Post mortem investigations subsequently revealed evidence of past mumps infection; Only virus isolated was an echovirus type 25 from nasopharyngeal secretions; MD felt pts meningoencephalitis & death not re:vax
CDC Split Type: WAES91120207

Write-up: 10 days following vax pt devel vomiting & h/a; 72 hrs following these sx, pt was hospitalized; On admission pt was afebrile & semiconscious; 48 hrs following hospitalization pt died; Post mortem investigations past mumps infection;


Result pages: prev   19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37   next

New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?EVENTS=ON&PAGENO=28&VAX[]=MEA&VAX[]=MER&VAX[]=MM&VAX[]=MMR&VAX[]=MMRV&VAXTYPES[]=Measles&DIED=Yes&VAX_YEAR_HIGH=2018&VAX_MONTH_HIGH=11


Copyright © 2020 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166